Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study
Adrienne Y L Chan, A. Yuen, Daniel Hsiang‐Te Tsai, Wallis C. Y. Lau, Yogini Jani, Yingfen Hsia, David Osborn, Joseph Hayes, Frank Besag, Edward Chia‐Cheng Lai, Li Wei, Katja Taxis, Ian Chi Kei Wong, Kenneth K. C. Man
Abstract
Recent studies raised concerns about the increasing use of gabapentinoids in different countries. With their potential for misuse and addiction, understanding the global consumption of gabapentinoids will offer us a platform to examine the need for any interventional policies. This longitudinal trend study utilised pharmaceutical sales data from 65 countries and regions across the world to evaluate the global trends in gabapentinoid consumption between 2008-2018. The multinational average annual percentage change of gabapentinoid consumption was +17.20%, increased from 4.17 defined daily dose per ten thousand inhabitants per day (DDD/TID) in 2008 to 18.26 DDD/TID in 2018. High-income countries had the highest pooled gabapentinoid consumption rate (39.92 DDD/TID) in 2018, which was more than six times higher than the lower-middle income countries (6.11 DDD/TID). The study shows that despite differences in healthcare system and culture, a consistent increase in gabapentinoid consumption is observed worldwide, with high-income countries remaining the largest consumers.